Prostate cancer Cancer
Conditions
Interventions
The participants' relugolix dose and regime will already be decided by their doctor and participating in this study will not alter this in any way.
Patients will undergo clinical assessments and rec
Sponsors
Accord healthcare
Eligibility
Sex/Gender
Male
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Patient who had voluntarily signed and dated the informed consent form 2. Male patients aged 18 years or older 3. Patients who had histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate described in the patient’s file 4. Patients deemed eligible for androgen-deprivation therapy with relugolix prescribed as part of standard clinical practice. 5. Patient who has agreed with the investigator the initiation of relugolix, per the investigator's decision, prior to enrolment into the study 6. Intended duration of androgen-deprivation therapy of at least twelve months
Exclusion criteria
Exclusion criteria: 1. Patient unable to provide informed consent 2. History of surgical castration 3. Intended duration of androgen-deprivation therapy of less than 12 months 4. Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of the product information 5. Patient who has already received or is currently receiving relugolix 6. Participants who are not treated in line with current Summary of Product Characteristics for relugolix
Countries
England, France, Germany, Ireland, Italy, Romania, Spain, United Kingdom
Contacts
Public ContactBrigitta Hunter
Outcome results
None listed